Loading
Genomics and Rare Diseases · Journal article
PLOS Digital Health · August 31, 2026
Early or partial results. Treat as a signal, not a conclusion.
This report describes the technical implementation and validation of California's SARS-CoV-2 Integrated Genomic Epidemiology Database (IGED), a statewide system linking 801,418 viral sequences with patient metadata. The system demonstrates feasibility of standardizing and integrating genomic surveillance across heterogeneous laboratory data sources, with good concordance to external reference databases, but the report does not measure clinical or public health outcomes from surveillance use.
Descriptive surveillance system implementation report. All laboratories in California performing SARS-CoV-2 whole genome sequencing under Title 17 regulatory requirement (July 2021 onwards). Anonymized viral sequences linked to patient-level epidemiologic metadata.. Intervention: Statewide mandatory reporting and integration of SARS-CoV-2 whole genome sequencing results into centralized IGED database with standardization and deduplication protocols.. n = 801,418. California.
801,418 sequences linked to patient-level metadata, representing 81.7% of all sequences reported in California Lineages reported to IGED showed strong concordance with lineage proportions in GISAID Sequencing results had average turnaround times longer than one month
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This infrastructure enables public health agencies to conduct real-time genomic surveillance of emerging variants, but the report itself does not demonstrate whether the system improved outbreak detection, response speed, or public health outcomes. Clinicians should recognize this as a foundational data system whose utility depends on how surveillance insights are translated into action.
This is a descriptive implementation report of a state surveillance database system, not a hypothesis test or clinical trial; it documents infrastructure development and data integration feasibility without measuring a clinical or public health intervention outcome.
As stated by the source record.
Quoted from the source exactly as published.
This infrastructure enables public health agencies to conduct real-time genomic surveillance of emerging variants, but the report itself does not demonstrate whether the system improved outbreak detection, response speed, or public health outcomes. Clinicians should recognize this as a foundational data system whose utility depends on how surveillance insights are translated into action.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
In July 2021, the California Code of Regulations Title 17 required all laboratories performing SARS‑CoV‑2 whole genome sequencing (WGS) to report their sequencing results to the California Department of Public Health (CDPH). These viral genomic data and patient metadata were compiled into the Integrated Genomic Epidemiology Database (IGED). Linking anonymized viral sequences with patient‑level information enabled monitoring of infectiousness, pathogenicity, transmission dynamics, evolution, and vaccine evasion among emerging SARS‑CoV‑2 lineages. Laboratories performing SARS-CoV-2 WGS transmitted sequencing results to CDPH through Electronic Laboratory Reporting (ELR) and non-ELR pathways. CDPH applied uniform reporting requirements but allowed flexibility in specific data formats to accommodate diverse data systems. To preserve data quality and interoperability across heterogeneous sources, CDPH implemented standardization, validation, and deduplication protocols. Snowflake, a cloud‑based data storage and analytics platform, and Posit Connect, a cloud deployment and automation platform, supported the management, processing, and integration of data within the IGED. The IGED established links between SARS‑CoV‑2 WGS data and epidemiologic metadata for 801,418 sequences, representing 81.7% of all sequences reported in California. Lineages reported to the IGED showed strong concordance with lineage proportions in GISAID. Sequences reported to the IGED had average turnaround times longer than one month, and the majority of sequencing was performed in Southern California and Los Angeles. The IGED enhanced genomic surveillance through predictive modeling and monitoring concerning evolutionary trends such as recombination and saltations in persistent infections. Development of the IGED highlighted the need for standardized data requirements, sustained funding for sequencing, incentives for data submission, and interdisciplinary collaboration to build an effective genomic surveillance system. This framework for linking genomic and epidemiologic data has not only generated critical insights for SARS‑CoV‑2 but also provided the foundation for CDPH and other public health organizations to develop similar IGED‑like systems for other priority pathogens as genomic surveillance expands.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.